| Mean (SD)/Proportion |  |  | |
---|---|---|---|---|
 | Intervention (n = 120) | Control (n = 108) | Difference between means (95% CI)/proportions | p-value |
PAI score | ||||
 Baseline | 2.62 (2.56) | 3.03 (2.61) |  |  |
 Follow-up | 4.15 (3.03) | 3.50 (3.08) |  |  |
 Change, p-value | 1.53 (2.82), < 0.001c | 0.46 (2.93), 0.155c | 1.07 (0.21 to 1.93) | 0.015a |
 ANCOVA |  |  | 0.90 (0.10 to 1.70) | 0.028 |
Activity level | ||||
 Inactive (PAI 0–0.04) | ||||
  Baseline | 21 (22.8%) | 17 (20.5%) |  |  |
  Follow-up | 7 (7.6%) | 13 (15.7%) |  |  |
  Change, p-value | -14 (15.2%), < 0.001d | -4 (4.8%), 0.332d | 10.4% | 0.119b |
 Low activity (PAI 0.05–1.5) | ||||
  Baseline | 23 (25%) | 13 (15.7%) |  |  |
  Follow-up | 15 (16.3%) | 15 (18.1%) |  |  |
  Change, p-value | -8 (8.7%), p = 0.144d | 2 (2.4%), 0.617d | 11.1% | 0.144b |
 Medium activity (PAI 1.51–3.75) | ||||
  Baseline | 28 (30.4%) | 31 (37.3%) |  |  |
  Follow-up | 36 (39.1%) | 31 (37.3%) |  |  |
  Change, p-value | 8 (8.7%), 0.157d | 0 | 8.7% | 0.414b |
 High activity (PAI 3.76–15) | ||||
  Baseline | 20 (21.7%) | 22 (26.5%) |  |  |
  Follow-up | 34 (37%) | 24 (28.9%) |  |  |
  Change, p-value | 14 (15.3%), 0.003d | 2 (2.4), 0.71d | 12.9% | 0.130b |
 VO2peak ml/kg/min | ||||
  Baseline | 29.0 (6.7) | 29.2 (6.1) |  |  |
  Follow-up | 28.4 (6.6) | 28.7 (7.2) |  |  |
  Change, p-value | -0.7 (4.2), 0.117c | -0.5 (6.4), 0.443c | -0.1 (-1.67 to 1.39) | 0.854a |
  ANCOVA |  |  | -0.2 (-1.63 to 1.26) | 0.803 |
 VO2peak l/min | ||||
  Baseline | 2.67 (0.7) | 2.67 (0.8) |  |  |
  Follow-up | 2.64 (0.7) | 2.63 (0.9) |  |  |
  Change, p-value | -0.04 (0.4), 0.344c | -0.04 (0.5), 0.397c | -0.01 (-0.11 to 0.13) | 0.927a |
  ANCOVA |  |  | -0.01 (-0.11 to 0.12) | 0.915 |
 WHO5 standardized %score | ||||
  Baseline | 59.78 (17.96) | 64.65 (17.22) |  |  |
  Follow-up | 69.14 (17.62) | 68.95 (16.34) |  |  |
  Change, p-value | 9.36 (15.33), < 0.001c | 4.30 (13.22), 0.005c | 5.06 (0.68 to 9.45) | 0.024a |
  ANCOVA |  |  | 3.28 (-0.69 to 5.25) | 0.104 |